Chimiothérapie néoadjuvante à base de carboplatine dans les cancers du sein triple négatifs PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Chimiothérapie néoadjuvante à base de carboplatine dans les cancers du sein triple négatifs PDF full book. Access full book title Chimiothérapie néoadjuvante à base de carboplatine dans les cancers du sein triple négatifs by Lynn Rob. Download full books in PDF and EPUB format.
Author: Lynn Rob
Publisher:
ISBN:
Category :
Languages : fr
Pages : 272
Get Book Here
Book Description
Author: Lynn Rob
Publisher:
ISBN:
Category :
Languages : fr
Pages : 272
Get Book Here
Book Description
Author: Antoine Guiheneuf
Publisher:
ISBN:
Category :
Languages : fr
Pages : 176
Get Book Here
Book Description
Patientes : 83 patientes ont eu un cancer du sein « triple négatif » (CSTN), traitées par chimiothérapie première entre 2002 et 2009. On compare les caractéristiques morphologiques et histologiques obtenues sur la micro-biopsie initiale entre les patientes ayant une réponse histologique complète (RHC) et celles n'ayant pas une RHC. Résultats : 26 % des patientes ont eu une RHC. Une association d'anthracyclines-taxanes (A-T) entraîne plus de RHC que l'utilisation d'anthracyclines seules (p=0,03). Un Ki-67 > 20 % est prédictif de RHC. On retrouve une tendance entre un âge inférieur à 50 ans et RHC (p=0,08) mais également entre une embole vasculaire sur la biopsie et une RHC (p=0,06). Il y a également un bénéfice en terme de survie sans récidive (p=0,02) dans le groupe RHC. Conclusion : Les patientes ayant un CSTN pouvant espérer un bénéfice à une chimiothérapie néoadjuvante à base d'A-T sont les patientes jeunes sans embole et avec un Ki-67 élevé sur la biopsie.
Author: Gw Sledge
Publisher: Clinical Pub
ISBN: 9781846920660
Category : Breast
Languages : en
Pages : 0
Get Book Here
Book Description
This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.
Author: Monica Morrow
Publisher: PMPH-USA
ISBN: 9781550092608
Category : Breast
Languages : en
Pages : 328
Get Book Here
Book Description
Managing Breast Cancer Risk is a single source for information needed by primary care physicians, nurses, gynecologists, as well as oncologic specialists who deal with women who are concerned about breast cancer. Its purpose is to bring together a multidisciplinary group of experts to address breast cancer risk in a clinically meaningful way. Chapters providing detailed information on individual risk factors are accompanied by a discussion of models, which integrate multiple factors for a more complete assessment of risk. Traditional strategies for risk management, including surveillance and prophylactic surgery, are reviewed, and the data on newer techniques such as ductal lavage and screening with magnetic resonance is presented. The rational for chemoprevention with selective estrogen receptor modulators (SERMS) is discussed, and the evidence for tamoxifen as a chemopreventative is updated. The potential for chemoprevention with newer SERMS and the aromatase inhibitors is reviewed. Finally, the critical (and often ignored) areas of quality of life and symptom management are addressed.
Author: Carsten Bokemeyer
Publisher: Elsevier Science Health Science Division
ISBN: 9780080445755
Category : Medical
Languages : en
Pages : 304
Get Book Here
Book Description
Author: Andrew D. Norden
Publisher: Springer Science & Business Media
ISBN: 160761166X
Category : Medical
Languages : en
Pages : 568
Get Book Here
Book Description
This comprehensive, yet practical, text is a ready collection of the most up-to-date information on primary CNS tumors. Authored by a carefully selected group of the world’s leading clinicians and scientists, the book is divided into three sections. The opening chapters cover general principles, including epidemiology, pathogenesis, tumor stem cells, supportive care, complications of therapy, and quality of life. The remaining two sections are comprised of treatment-oriented chapters covering the spectrum of gliomas and rarer tumor types. Each of these chapters presents multi-disciplinary therapeutic approaches and addresses specific disease concerns. Throughout, the authors incorporate the cutting-edge advances in molecular biology and genomics that are revolutionizing neuro-oncology. The result is an important clinical resource which provides evidence-based data and interpretation essential to intelligent therapeutic decision making.
Author: Rodney R. Million
Publisher: Lippincott Williams & Wilkins
ISBN:
Category : Medical
Languages : en
Pages : 944
Get Book Here
Book Description
Revised and updated, this edition provides a comprehensive, authoritative approach to head and neck cancer. Page after page is packed with clear and instructive illustrations - line drawings and halftones; fibre optic and microscopic examinations; CT scans; before and after treatment figures; plus many full-colour illustrations.
Author: Onder Ofluoglu
Publisher: Clinics: Orthopedics
ISBN: 9781437705140
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
Every Clinics issue brings you todayÆs best thinking on the challenges you face. Whether you purchase these issues individually, or order a personal subscription (which includes online access to current and past issues at www.theclinics.com), the Clinics offer you an efficient way to update your know howàone issue at a time. Book jacket.
Author: Joseph Wybran
Publisher: Elsevier
ISBN: 1483140156
Category : Medical
Languages : en
Pages : 299
Get Book Here
Book Description
Clinical Tumor Immunology contains the proceedings of the Symposium of Clinical Tumor Immunology held in Brussels, Belgium, on May 26-29, 1975) and organized by the European Organization for Research on Treatment of Cancer in cooperation with the Department of Immunology of the University Hospital of Brussels. The papers explore progress in the field of clinical tumor immunology and cover topics ranging from general mechanisms in tumor immunity to tumor antigens and immunotherapy. A classification of leukemias and lymphomas is also presented. Comprised of 48 chapters, this book begins with an overview of the biological activities of the circulating thymic hormone, followed by a discussion on macrophage secretions affecting the growth of other cells. The reader is then introduced to immune cellular mechanisms at the site of the tumor; the use of the leukocyte migration technique in studies of tumor-directed cellular immunity in malignant melanoma; and immunological approaches to the identification of leukemic cells. Subsequent chapters deal with preclinical approaches in tumor immunochemotherapy; mediation of immune responses to human tumor antigens with "immune" RNA; and the role of transfer factor in human cancer. This monograph will be of interest to oncologists and immunologists.
Author: G. Mathe
Publisher: Springer
ISBN: 9783642808500
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
G. MATHE and R. K. OLDHAM'~ Institut de Cancerologie et d'Immunogem!tique, Hopital Paul Brousse, Villejuif Since the last war, cancer chemotherapy has been the object of very intensive and expensive research. Nevertheless, its development has been very slow, and its ultimate potential is today somewhat in doubt. In doubt because it does not cure any cancer patients except a) females carrying placental choriocarcinoma, a semi-allogenic tumor, in which case, cure may be in fluenced by immune rejection, and b) children suffering from Burkitt's tumor, where the probable reason for the cure is that all the neoplastic cells are in the cycle, which is a unique condition among all the human tumor varieties. Whether the long term survivors in acute leukemia, lymphomas, certain sarcomas and certain testicular tumors are "cures" will require longer follow-up. The idea that chemotherapy does not cure most cancer patients because all their neoplastic cells are not in cycle has led to the use of drug combinations. Whatever they are, "cocktail combinations" which are made up of drugs given according to any timing, or scientific combinations, based on pharmacodynamics, pharmaco kinetics or cell kinetics data, are more toxic than single drugs, and are all the more toxic as the number of drugs in the combination is increased.
